নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

bluefish pharmaceuticals ab - bikalutamid - tablett, filmdrasjert - 150 mg

নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

teva sweden ab - bikalutamid - tablett, filmdrasjert - 150 mg

নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

laboratoires juvisé pharmaceuticals - bikalutamid - tablett, filmdrasjert - 150 mg

নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

orifarm as - bikalutamid - tablett, filmdrasjert - 150 mg

নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

orifarm as - bikalutamid - tablett, filmdrasjert - 150 mg

ইউরোপীয় ইউনিয়ন - নরওয়েজীয় - EMA (European Medicines Agency)

sanofi b.v. - thyrotropin alfa - skjoldbrusk neoplasmer - fremre hypofysen lapp hormoner og analoger, hypofysen og hypothalamus hormoner og analoger - thyrogen is indicated for use with serum thyroglobulin (tg) testing with or without radioiodine imaging for the detection of thyroid remnants and well-differentiated thyroid cancer in post thyroidectomy patients maintained on hormone suppression therapy (thst). low risk patients with well-differentiated thyroid carcinoma who have undetectable serum tg levels on thst and no rh (recombinant human) tsh-stimulated increase of tg levels may be followed-up by assaying rh tsh-stimulated tg levels. thyrogen is indicated for pre-therapeutic stimulation in combination with a range of 30 mci (1. 1 gbq) to 100 mci (3. 7 gbq) radioiodine for ablation of thyroid tissue remnants in patients who have undergone a near-total or total thyroidectomy for well-differentiated thyroid cancer and who do not have evidence of distant metastatic thyroid cancer (see section 4.

নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

sandoz - københavn - leuprorelinacetat - implantat - 5 mg

নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

medical valley invest ab - letrozol - tablett, filmdrasjert - 2.5 mg

ইউরোপীয় ইউনিয়ন - নরওয়েজীয় - EMA (European Medicines Agency)

accord healthcare s.l.u. - degarelix acetate - prostata neoplasmer - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.